{"id":11154,"date":"2022-08-25T00:00:00","date_gmt":"2022-08-25T05:00:00","guid":{"rendered":"https:\/\/myeloma.ca\/1970\/01\/01\/fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire\/"},"modified":"2025-08-19T08:28:14","modified_gmt":"2025-08-19T13:28:14","slug":"fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2022\/08\/25\/fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire\/","title":{"rendered":"FDA accorde la d\u00e9signation de traitement r\u00e9volutionnaire au talquetamab pour le my\u00e9lome r\u00e9cidivant\/r\u00e9fractaire"},"content":{"rendered":"<p>The FDA has granted a breakthrough therapy designation to talquetamab for use as a potential therapeutic option in patients with relapsed or refractory multiple myeloma who received at least 4 prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody.<\/p>\n<p><strong><a href=\"https:\/\/www.onclive.com\/view\/fda-grants-breakthrough-therapy-designation-to-talquetamab-for-relapsed-refractory-myeloma\" target=\"_blank\" rel=\"noopener\">Lire la suite ici<\/a><\/strong>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The FDA has granted a breakthrough therapy designation to talquetamab for use as a potential therapeutic option in patients with relapsed or refractory multiple myeloma who received at least 4 prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody. Lire la suite ici.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[53,50,58,52],"tags":[],"class_list":["post-11154","post","type-post","status-publish","format-standard","hentry","category-actualites-et-evenement","category-news-events","category-nouvelles-de-myelome-canada","category-whats-new-at-myeloma-canada"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11154","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=11154"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11154\/revisions"}],"predecessor-version":[{"id":31283,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11154\/revisions\/31283"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=11154"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=11154"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=11154"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}